Men taking Viagra and Cialis to solve their impotence problems may face new concerns, such as partial loss of their eyesight. Reports of partial vision loss in 38 men have prompted the Food and Drug Administration (FDA) to request Viagra manufacturer, Pfizer, change labels alerting patients to the possible risk. Eli Lilly & Co., the manufacturer of Cialis, has already made the change to its label.
The news isn’t good for women looking to begin or resume hormone replacement therapy (HRT), such as Prempro, to offset menopause symptoms. A new report shows increased links between HRT and recurring breast cancer. The study’s results only increase the weight of initial evidence announced three years ago, linking the hormones estrogen and progestogen to higher cancer risks.
Check out your medicine cabinet. Do any of your prescription drugs have a black box on the label? That’s the strongest warning given to medication that could pose more health risks than benefits. Concerned critics raise the issue that the black-box warning isn’t enough and more needs to be done to educate physicians, patients and pharmacists about the potential dangers of prescription drugs identified with the black rectangular warning labels.
Do you have high cholesterol? If so, you may be one of the millions of people taking Crestor. And that’s what worries the consumer interest group, Public Citizen. The group is criticizing the Food and Drug Administration (FDA) for not pulling Crestor from the market amid reports that the drug has six times higher the risk of muscle damage compared to other cholesterol-lowering drugs.
Do you have an elderly family member suffering from dementia? If so, check their medicine cabinet. The Food and Drug Administration (FDA) has issued “black box” warnings on seven antipsychotic drugs used to treat behavioral problems in elderly patients with dementia. Older patients taking the antipsychotic drugs are more likely to die prematurely, according to the FDA’s findings.
There’s more bad news for Vioxx and its manufacturer Merck & Co.
The drugmaker's researchers privately raised concerns back in 2000 that Vioxx might increase cardiovascular side effects. Those concerns were being raised even as Merck was downplaying a study that highlighted the pain relief medication's potential heart attack risk.